SAENGER BRADLEY 4

What Happened
Bradley Saenger, Chief Financial Officer of Tonix Pharmaceuticals (TNXP), acquired 1,453 shares on 2026-06-30 at $10.91 per share, a total transaction value of $15,858. The acquisition is reported as an "other acquisition or disposition" (code J) and is tied to the company's 2025 Employee Stock Purchase Plan.

Key Details

• Transaction date: 2026-06-30; Price: $10.91 per share; Shares acquired: 1,453; Total value: $15,858.
• Transaction code: J (other acquisition or disposition).
• Footnote: Shares were acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan (ESPP).
• Shares owned after transaction: Not disclosed in this filing.
• Filing date: 2026-07-09 — filed 9 days after the transaction date, which is later than the typical two-business-day Form 4 reporting requirement.

Context
ESPP purchases are a common employee benefit where shares are bought at periodically set prices through payroll deductions; such purchases are often routine and do not necessarily indicate the insider's short-term market view. This was a purchase (acquisition), which investors generally view as more informative than routine sales, but the ESPP context is important when interpreting the signal. The late filing reduces timeliness of disclosure but does not change the underlying acquisition details.